dc.contributor.author | Abdul Salam Ahmed, Asma | |
dc.date.accessioned | 2020-09-28T10:20:15Z | |
dc.date.available | 2020-09-28T10:20:15Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/2001 | |
dc.description | TCRs (T-cell receptors) are expressed by T cells, and profoundly and actively
influence lymphocyte activity in modulating the immune response. Manipulating T
cell receptor properties and numbers to boost immune responses is a very active area
of immunotherapy research. TILs (tumor-infiltrating lymphocytes) are being actively
investigated for their anti-cancer properties, as tumor biopsies often contain immune
cells conditioned to the tumor microenvironment. These cells can be harvested,
studied, and subjected to chemokine fortification prior to reintroduction. So, CAR-T
cells (chimeric antigen receptor-T cells) refers to genetically engineered T cells which
express surface receptors specifically targeting cancer cell-expressed surface antigen.
(1)
CARs are engineered fusion proteins that contain an extracellular antigen-binding
domain composed of a single chain variable fragment derived from an antibody and
intracellular signaling domains, which are involved in the initiation of T-cell signaling
and downstream T-cell effector functions . | en_US |
dc.description.abstract | T cells expressing chimeric antigen receptors (CART) have shown significant promise
in clinical trials to treat hematologic malignancies, but their efficacy in solid tumors
has been limited ,It's because solid tumors don't seem to be the identical . Oncolytic
viruses have the potential to act in synergy with immunotherapies because of their
immunogenic oncolytic properties and also the opportunity of incorporating
therapeutic transgenes in their genomes. hypothesized that an oncolytic adenovirus
armed with an EGFR-targeting, bispecific T-cell engager (OAd-BiTE) would improve
the end result of CART-cell therapy in solid tumors. demonstrated that OAd-BiTE–
mediated oncolysis significantly improved CART-cell activation and proliferation,
while increasing cytokine production and cytotoxicity, and showed an in vitro
favorable safety profile. BiTEs secreted from infected cells redirected CART cells
toward EGFR within the absence of FR-a, thereby addressing tumor heterogeneity.
BiTE secretion also redirected CAR-negative, nonspecific T cells found in CART-cell
preparations toward tumor cells. | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | How to eliminate solid tumors by CAR T-cell therapy | en_US |
dc.type | Other | en_US |